Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study.
about
Erythropoietin or darbepoetin for patients with cancerDrug therapy for the management of cancer-related fatigueErythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient dataDrug therapy for the management of cancer related fatigueErythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient dataErythropoietin or Darbepoetin for patients with cancerEffects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished dataThe Value of Patient Reported Outcomes and Other Patient-Generated Health Data in Clinical Hematology.Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trialErythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.Erythropoiesis-stimulating agents in the management of cancer patients with anemia: a meta-analysis.Erythropoietin action in stress response, tissue maintenance and metabolism.Transfusions and patient burden in chemotherapy-induced anaemia in FranceThe ESA APPRISE Oncology Program: A History of REMS Requirements, a Review of the Data, And an Approach to Compliance in the Hospital.Erythropoietin, a novel versatile player regulating energy metabolism beyond the erythroid systemMeta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials.Overview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia.Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer.Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY.Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia.Functional EpoR pathway utilization is not detected in primary tumor cells isolated from human breast, non-small cell lung, colorectal, and ovarian tumor tissues.Impact of safety concerns and regulatory changes on the usage of erythropoiesis-stimulating agents and RBC transfusionsRandomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation.Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy.Medical uses of erythropoietin.Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.Darbepoetin alfa for the treatment of cancer-related anemia: an update.Optimising anaemia management with epoetin beta.Evolving treatment strategies for anaemia in cancer: experience with epoetin beta.The burden of anaemia in patients with cancer.Strategies to optimize the use of erythropoietin and iron therapy in oncology patients.Management of cancer anemia.European Myeloma Network guidelines for the management of multiple myeloma-related complications.Management of cancer-related fatigue.Once-weekly treatment of anemia in patients with cancer: a comparative review of epoetins.Trends in Anemia Management in Hemodialysis Patients with CancerThe development of erythropoietic agents in oncology.Anaemia of cancer: impact on patient fatigue and long-term outcome.
P2860
Q24202335-A0304383-1DC9-4032-B69E-191E16204AFBQ24234267-D1C45F15-839D-4D24-B9B9-39B7455FAB5FQ24240202-999C8D65-7863-4780-8E03-C588A630140AQ24242050-6258106F-2D68-4655-9BEC-C1C7D89867D8Q24242864-707233B4-93A1-45D2-8B3A-966FF997F122Q24245464-CFD598CE-3057-47C7-8B1B-E7607E8F6C39Q30803363-FA569C78-A8D0-43FB-95F2-BA9748EE2F35Q30964688-A9ECEBB0-7C9C-493F-BAD6-46D91F09CA9EQ33243661-9C6D43AE-ED4E-4CAD-BA0B-6698559AB3B9Q33499897-9FB82E5B-341B-438B-9620-2F568D3AC81EQ33630871-805921ED-87BE-481F-9F03-78409CB30E6DQ33727356-6D34A771-582D-4342-9009-FA0FC6524B6DQ33827405-3629B3AC-48DE-46FD-B5C4-446E43E7FC6DQ33907747-FCF4E26E-68DB-4960-88CE-AEDC0B21D8F6Q33937375-C6C84D92-CD70-446B-BB97-8823934F24A1Q34022950-82DF3EE5-69AD-41D4-A5B6-5608432FDE5EQ34100489-ADE54263-A560-4944-A353-E9168175A70FQ34554073-8101BBEF-1C24-43EA-9F3D-192D45B9C2F0Q34635638-0A338BBE-188A-4FCD-8FC6-46E542450ECEQ34961213-9689541D-09AB-41D5-AE6C-F92F379E4F9BQ35104268-A29423D5-967C-4D1A-9AA1-B86C0C5AF428Q35166812-33C92DDB-6E2E-4831-865E-11D1B22F4BDEQ35217404-7E3B8A22-F7F0-4D62-BEDA-ECC984FC5EEFQ35583842-59859EA0-9FBB-427F-9E0D-A79745C26501Q35620681-13937887-C082-4296-AF4F-28BB5167BEDAQ35696941-62A8B7BF-864A-4B4D-9484-4F4837C51BFBQ35812964-D55B2DE9-6237-4D7A-B168-3312F322EBE2Q35858979-27E9215A-D1AF-45A9-903F-FF370F92EFBCQ35918431-85521E02-42EA-4380-A405-44A8A5E3C66EQ35919225-47C5C420-6FEB-4235-86D4-7F655D8C8C7BQ35919230-33C4025E-5C0D-4B01-968C-9D35BF782DF5Q35920738-F8E778A6-682B-4E0D-AFAC-E0312F39071CQ35976513-C31553E8-CA64-4FB6-B416-C81A06CEF8F0Q36028737-51DD795E-7383-4621-A2D8-9B47BA5C42C2Q36115636-01E71F41-5334-419D-BCFA-89CDF3745BDFQ36156911-7A2FCE04-F769-4EB9-97C4-F47C645BD146Q36193223-CEB079E2-8FF5-44A6-95CE-E638281B80DCQ36200205-5EECD5F9-4DEF-4BCE-9538-F3E5E9AC21E4Q36219651-240453C2-C120-4FA8-B379-0B3761C8BCAAQ36294781-8D6CBECC-B984-4BA3-B685-3BA05C005DC6
P2860
Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Efficacy and safety of darbepo ...... ind, placebo-controlled study.
@ast
Efficacy and safety of darbepo ...... ind, placebo-controlled study.
@en
Efficacy and safety of darbepo ...... ind, placebo-controlled study.
@nl
type
label
Efficacy and safety of darbepo ...... ind, placebo-controlled study.
@ast
Efficacy and safety of darbepo ...... ind, placebo-controlled study.
@en
Efficacy and safety of darbepo ...... ind, placebo-controlled study.
@nl
prefLabel
Efficacy and safety of darbepo ...... ind, placebo-controlled study.
@ast
Efficacy and safety of darbepo ...... ind, placebo-controlled study.
@en
Efficacy and safety of darbepo ...... ind, placebo-controlled study.
@nl
P2093
P2860
P921
P1476
Efficacy and safety of darbepo ...... ind, placebo-controlled study.
@en
P2093
Albert Altés
Andrew Belch
Darbepoetin Alfa 20000161 Study Group
David Watson
Eeva Juvonen
Gregory Rossi
James Matcham
Jesus San Miguel
Kerry Taylor
Magnus Adriansson
P2860
P304
P356
10.1046/J.1365-2141.2003.04448.X
P407
P577
2003-08-01T00:00:00Z